STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
comments(0)
5-min edit window · permanent after that